<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-125954" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Drug Distribution</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Onetto</surname>
            <given-names>Andr&#x000e9;s J.</given-names>
          </name>
          <aff>AUACOM, Florida International University Herbert Wertheim College of Medicine Clerkship Program</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharif</surname>
            <given-names>Sairah</given-names>
          </name>
          <aff>St Francis Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andr&#x000e9;s Onetto declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sairah Sharif declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-125954.s1" sec-type="Definition/Introduction">
        <title>Definition/Introduction</title>
        <p content-type="pubmed-excerpt">Pharmacokinetics is the study of a drug moiety or a compound as it moves through the body after its administration. It involves the processes of drug absorption, bioavailability, clearance, and distribution.<xref ref-type="bibr" rid="article-125954.r1">[1]</xref>&#x000a0;Although these processes are theoretically separate, from a practical standpoint in-vivo, they are all inter-connected. After the drug is absorbed from the site of administration, it is distributed to extracellular fluids.<xref ref-type="bibr" rid="article-125954.r2">[2]</xref>&#x000a0;High reserves of plasma protein-bound drugs can cause prolonged effects by creating a sustained release mechanism.<xref ref-type="bibr" rid="article-125954.r3">[3]</xref>&#x000a0;</p>
        <p>Drug distribution is the disbursement of an unmetabolized drug as it moves through the body&#x02019;s blood and tissues. The efficacy or toxicity of a drug depends on the distribution in specific tissues and in part explains the lack of correlation between plasma levels and the effects that are seen. Based on the molecular structure, drugs have variable distribution in different types of tissues such as fat, muscle, and brain. Unlike other tissues, the brain and testes are unique, as they contain membrane barriers making a drug significantly less susceptible to distribution.<xref ref-type="bibr" rid="article-125954.r4">[4]</xref>&#x000a0;Based on lipid and non-lipid solubility, drugs can be classified as lipophilic or hydrophilic described below.&#x000a0;</p>
        <p>
<bold>Lipophiliic (Fat Soluble)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nonpolar compounds</p>
          </list-item>
          <list-item>
            <p>Easily diffuse across lipid bilayers of cell membranes</p>
          </list-item>
          <list-item>
            <p>Rx can be administered topically</p>
          </list-item>
          <list-item>
            <p>Free diffusion across the blood-brain barrier</p>
          </list-item>
          <list-item>
            <p>Biotransformed in the liver&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Excreted through the bile duct</p>
          </list-item>
        </list>
        <p>
<bold>Hydrophilic (Water Soluble)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Polar compounds</p>
          </list-item>
          <list-item>
            <p>Cross lipid bilayers via facilitated transport (passive chemical diffusion across a cell membrane by ion channels or carriers)</p>
          </list-item>
          <list-item>
            <p>Eliminated by kidneys</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-125954.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>Drug distribution is impacted by several factors related to the drug and the body. The drug-related factors include blood and tissue binding proteins, pH, and perfusion. The body-related factors include body water composition, fat composition, diseases (e.g., volume depletion, burns, third spacing).</p>
      </sec>
      <sec id="article-125954.s3" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>As&#x000a0;people age, the overall body water reduces. However, intracellular water remains relatively stable from the first month of life to adulthood. Higher doses of drugs per kilogram weight are required in younger children as they have a higher percentage of water.<xref ref-type="bibr" rid="article-125954.r5">[5]</xref>&#x000a0;Lipophilic drugs are more likely to distribute to areas of high lipid density.<xref ref-type="bibr" rid="article-125954.r6">[6]</xref>&#x000a0;Body fat varies with age, gender and genetics. Many drugs are bound to plasma proteins, and the most important drug-binding proteins include albumin and globulins. The concentration of these proteins varies with age, nutritional status, and disease.</p>
        <p>Understanding drug distribution and pharmacokinetics (PK) is important for all clinicians prescribing medication, along with understanding the&#x000a0;fundamentals of protein binding.<xref ref-type="bibr" rid="article-125954.r7">[7]</xref>&#x000a0;Only&#x000a0;free and unbound drugs will pass from vascular spaces to tissues where a drug-receptor interaction will occur as well&#x000a0;as the effect of the drug.&#x000a0;Protein binding is not only affected by the concentration of protein but also the pH, metabolic abnormalities (hyperglycemia, uremia), and the presence of other chemicals that will compete for protein binding.</p>
        <p>Competition for plasma binding can influence drug effects. For example, Aspirin and Warfarin are known to compete for the same plasma protein binding site. Administering both drugs at the same time will increase the unbound drug, thereby potentiating their effects and potentially lead to bleeding risk.<xref ref-type="bibr" rid="article-125954.r8">[8]</xref>&#x000a0;For a drug to be effectively eliminated by the kidney, the drug must be metabolized from a lipophilic molecule into a polar molecule. The liver produces a polar metabolite of the drug, using two unique sets of reactions known as phase I metabolism and phase II metabolism.<xref ref-type="bibr" rid="article-125954.r9">[9]</xref>&#x000a0;</p>
        <p><italic toggle="yes">Phase I metabolism</italic>&#x000a0;involves what is known as the cytochrome P-450 system (CYP enzyme). CYP alters a drug in such a way so that it will be more amenable to combining with polar molecules. These reactions involve basic chemistry principles such as oxidation, reduction, or hydrolysis.&#x000a0;<italic toggle="yes">Phase II metabolism</italic>&#x000a0;is the process of adding a polar moiety to the drug, such as sulfate, acetate, or glucuronate. The addition of a polar moiety to a drug makes the drug water-soluble and available for excretion&#x000a0;by the kidney.&#x000a0;</p>
        <p>
<bold>Phases of Biotransformation&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Phase I reaction</bold>: The drug is first transformed into a polar metabolite via oxidation by the cytochrome P-450 system&#x000a0;&#x02192;&#x000a0;allows&#x000a0;phase II to occur.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Phase II reactions</bold>: Involves the coupling of the metabolite with&#x000a0;glucuronic acid, acetyl groups, sulfates, amino acids, or glutathione.</p>
          </list-item>
        </list>
        <p>
<bold>Types of Drug Kinetics</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Zero-order kinetics</bold><bold>:</bold>&#x000a0;The rate of metabolism/elimination remains constant and is&#x000a0;independent of the concentration of a drug.&#x000a0; &#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>First-order kinetics</bold><bold>:</bold>&#x000a0;The rate of metabolism/elimination is directly&#x000a0;proportional to the plasma concentration of the drug.</p>
          </list-item>
        </list>
        <p><bold>Half-life (T1/2):&#x000a0;</bold>The&#x000a0;time required for a drug's plasma concentration to reach half of its initial value.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>After 4&#x000a0;</bold><bold>half-lives&#x000a0;</bold><italic toggle="yes">&#x0003e;</italic> 90%&#x000a0;of the drug is eliminated.</p>
          </list-item>
        </list>
        <p><bold>Drug clearance:&#x000a0;</bold>The&#x000a0;measure of the rate of drug elimination &#x02192; the plasma volume that can be completely cleared of the drug in a given period of time.&#x000a0;</p>
        <p>Additionally, uremia not only affects protein binding, but kidneys also play a significant role in drug absorption, distribution, metabolism, and excretion (ADME). Renal dose adjustment is essential in moderate to severe renal failure. Important strategies for managing and drug dosing must be adjusted accordingly, and the risks must be weighed against the benefits.<xref ref-type="bibr" rid="article-125954.r10">[10]</xref>&#x000a0;</p>
        <p>Several factors impact drug distribution. These factors include the concentration of drug transporters in blood, pH, perfusion, body water composition, body fat composition, and most certainly disease conditions (e.g., volume depletion, burns, third spacing). The majority of protein binding is relevant only when the drug is more than 90 percent protein bound. In the hypoalbuminemia state, which occurs in malnutrition and inflammation, there is a higher concentration of the unbound drugs. Body composition and metabolic factors also affect drug distribution. For example, during the last trimester of pregnancy, plasma volume expands, so there is an overall diluting effect on plasma proteins. There is also a change in adipose tissue. Additionally, pregnant women are frequently excluded in clinical trials related to drugs.<xref ref-type="bibr" rid="article-125954.r11">[11]</xref> In a critically ill patient, drug distribution also changes due to deranged physiology, protein binding changes, fluid shifts, pH changes, and vascular organ perfusion.<xref ref-type="bibr" rid="article-125954.r12">[12]</xref>&#x000a0;Thus it could be useful to monitor drug levels in these conditions if possible.</p>
        <p>The <bold>cytochrome P-450 system</bold> is a family of heme-containing enzymes found in the liver and intestinal tract. There are multiple forms of CYP enzymes. Some drugs can either induce or inhibit specific isoforms of the enzyme, affecting the ADME of a drug. A clinician must be aware of potential drug-drug interactions with CYP enzyme inducers and inhibitors and&#x000a0;naturally occurring compounds that can alter the actions of CYP enzyme. Naturally occurring compounds include grapefruit juice, nicotine-containing products, and St. John&#x02019;s wort.<xref ref-type="bibr" rid="article-125954.r13">[13]</xref><xref ref-type="bibr" rid="article-125954.r14">[14]</xref></p>
        <p>Below is a list of the major drugs that inhibit and induce the cytochrome P-450 system, as well as dugs that are a major substrate of the enzyme:&#x000a0;</p>
        <p>
<bold>CYP1A2</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Inhibitors:&#x000a0;amiodarone, cimetidine, ciprofloxacin, fluvoxamine</p>
          </list-item>
          <list-item>
            <p>Inducers:&#x000a0;carbamazepine, phenobarbital, rifampin, tobacco</p>
          </list-item>
          <list-item>
            <p>Substrates:&#x000a0;caffeine, clozapine, theophylline</p>
          </list-item>
        </list>
        <p>
<bold>CYP2C9</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Inhibitors:&#x000a0;amiodarone, fluconazole, fluoxetine, metronidazole, ritonavir, trimethoprim/sulfamethoxazole</p>
          </list-item>
          <list-item>
            <p>Inducers: carbamazepine, phenobarbital, phenytoin, rifampin</p>
          </list-item>
          <list-item>
            <p>Substrates:&#x000a0;carvedilol, celecoxib, glipizide, ibuprofen, irbesartan, losartan</p>
          </list-item>
        </list>
        <p>
<bold>CYP2C19</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Inhibitors:&#x000a0;fluvoxamine, isoniazid, ritonavir</p>
          </list-item>
          <list-item>
            <p>Inducers: carbamazepine, phenytoin, rifampin</p>
          </list-item>
          <list-item>
            <p>Substrates:&#x000a0;omeprazole, phenobarbital, phenytoin</p>
          </list-item>
        </list>
        <p>
<bold>CYP2D6</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Inhibitors:&#x000a0;amiodarone, cimetidine, diphenhydramine, fluoxetine, paroxetine, quinidine, ritonavir, terbinafine</p>
          </list-item>
          <list-item>
            <p>Inducers: none</p>
          </list-item>
          <list-item>
            <p>Substrates: amitriptyline, carvedilol, codeine, donepezil, haloperidol, metoprolol, paroxetine, risperidone, tramadol</p>
          </list-item>
        </list>
        <p>
<bold>CYP2E1</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Inhibitors: none</p>
          </list-item>
          <list-item>
            <p>Inducers: ethanol, isoniazid, tobacco</p>
          </list-item>
          <list-item>
            <p>Substrates: acetaminophen, theophylline, verapamil</p>
          </list-item>
        </list>
        <p>
<bold>CYP3A4 and CYP3A5</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Inhibitors:&#x000a0;clarithromycin, diltiazem, erythromycin, grapefruit juice, itraconazole, ketoconazole, nefazodone<bold>*</bold>, ritonavir, telithromycin, verapamil&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Inducers: carbamazepine,&#x000a0;Hypericum perforatum, phenobarbital, phenytoin, rifampin</p>
          </list-item>
          <list-item>
            <p>Substrates:&#x000a0;alprazolam, amlodipine, atorvastatin, cyclosporine, diazepam, estradiol, simvastatin, sildenafil, verapamil, zolpidem</p>
          </list-item>
        </list>
        <p>Below is an additional list of common drug-drug interactions involving the cytochrome P-450 system that clinicians should be aware of:&#x000a0;</p>
        <p>Drug:&#x000a0;<bold>amiodarone</bold>&#x000a0;</p>
        <p>CYP enzyme:&#x000a0;CYP2C9 and CYP3A4 inhibitor &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
        <p>Drug-Drug Interaction:&#x000a0;<italic toggle="yes">warfarin</italic>&#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
        <p>Metabolizing Enzyme:&#x000a0;CYP2C9&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <p>Side Effects: Increased risk of bleeding caused by increased warfarin level.</p>
        <p>Drug:&#x000a0;<bold>carbamazepine</bold>,<bold>&#x000a0;phenobarbital</bold>,<bold>&#x000a0;phenytoin</bold>&#x000a0;</p>
        <p>CYP enzyme:&#x000a0;CYP3A4 inducer &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <p>Drug-Drug Interaction:&#x000a0;<italic toggle="yes">Ethinyl estradiol-containing contraceptives</italic>&#x000a0;&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <p>Metabolizing Enzyme:&#x000a0;CYP3A4 &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <p>Side Effects: Unplanned pregnancy caused by reduced estradiol level.</p>
        <p>Drug:&#x000a0;<bold>clarithromycin</bold>,&#x000a0;<bold>erythromycin</bold>,&#x000a0;<bold>telithromycin</bold></p>
        <p>CYP enzyme: CYP3A4 inhibitor &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <p>Drug-Drug Interaction:&#x000a0;<italic toggle="yes">simvastatin, verapamil</italic>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <p>Metabolizing Enzyme:&#x000a0;CYP3A4 &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
        <p>Side Effects: Myopathy or rhabdomyolysis caused by increased simvastatin level. Hypotension and QT interval prolongation caused by increased verapamil level.</p>
        <p>Drug:&#x000a0;<bold>diltiazem</bold>,&#x000a0;<bold>verapamil</bold></p>
        <p>CYP enzyme:&#x000a0;CYP3A4 inhibitor &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <p>Drug-Drug Interaction:<italic toggle="yes">&#x000a0;prednisone &#x000a0; &#x000a0;</italic>&#x000a0;&#x000a0; &#x000a0; &#x000a0;</p>
        <p>Metabolizing Enzyme: CYP3A4 &#x000a0; &#x000a0; &#x000a0;</p>
        <p>Side Effects: Immunosuppression caused by increased prednisolone serum levels.</p>
        <p>Drug:&#x000a0;<bold>fluoxetine</bold>,&#x000a0;<bold>paroxetine</bold></p>
        <p>CYP enzyme:&#x000a0;CYP2D6 inhibitor &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <p>Drug-Drug Interaction:&#x000a0;<italic toggle="yes">risperidone, tramadol&#x000a0; &#x000a0; &#x000a0;</italic>&#x000a0;&#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <p>Metabolizing Enzyme:&#x000a0;CYP2D6 &#x000a0;&#x000a0;</p>
        <p>Side Effects: Increased risk of extrapyramidal adverse effects caused by increased risperidone level.</p>
        <p>Drug:&#x000a0;<bold>Grapefruit juice</bold></p>
        <p>CYP enzyme:&#x000a0;CYP3A4 inhibitor &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <p>Drug-Drug Interaction:&#x000a0;<italic toggle="yes">buspirone</italic>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <p>Metabolizing Enzyme:&#x000a0;CYP3A4 &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
        <p>Side Effects:&#x000a0;Dizziness and serotonin syndrome caused by increased buspirone level.</p>
        <p>Drug:&#x000a0;<bold>metronidazole</bold>&#x000a0;</p>
        <p>CYP enzyme:&#x000a0;CYP2C9 inhibitor &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
        <p>Drug-Drug Interaction:<italic toggle="yes">&#x000a0;warfarin &#x000a0; &#x000a0; &#x000a0;</italic>&#x000a0;&#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <p>Metabolizing Enzyme:&#x000a0;CYP2C9 &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <p>Side Effects: Increased risk of bleeding caused by increased warfarin level.</p>
        <p>Drug:<bold>&#x000a0;terbinafine</bold>&#x000a0;</p>
        <p>CYP enzyme:&#x000a0;CYP2D6 inhibitor &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
        <p>Drug-Drug Interaction:<italic toggle="yes">&#x000a0;amitriptyline &#x000a0; &#x000a0;</italic>&#x000a0;&#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <p>Metabolizing Enzyme:&#x000a0;CYP2D6 &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <p>Side Effects:&#x000a0;Dry mouth, dizziness, and cardiac toxicity caused by a prolonged increase in amitriptyline and nortriptyline.</p>
        <p><bold>CYP</bold>&#x000a0;= cytochrome P-450&#x000a0;</p>
      </sec>
      <sec id="article-125954.s4" sec-type="Nursing, Allied Health, and Interprofessional Team Interventions">
        <title>Nursing, Allied Health, and Interprofessional Team Interventions</title>
        <p>The interprofessional team and healthcare professionals, including laboratory technologists, pharmacists, nurses, and clinicians, need to all work together to ensure the safety and efficacy of administered drugs. After the clinician chooses the choice and dosage of a particular drug, the pharmacist should verify dosing, report any drug interactions, and take notice of special clinical situations that will influence drug levels and hence efficacy as well as adverse events (e.g., albumin levels, changes in weight, malnutrition, renal and hepatic function).&#x000a0;In one study in chronic kidney disease patients, pharmacists identified 5302 drug-related problems and made 3160 recommendations with acceptance rates up to 95%.<xref ref-type="bibr" rid="article-125954.r15">[15]</xref>&#x000a0;</p>
        <p>When possible and indicated plasma levels should be followed. Nurses play a critical role in drug administration and alerting the team regarding&#x000a0;errors related to medication reconciliation.<xref ref-type="bibr" rid="article-125954.r16">[16]</xref>&#x000a0;This team collaboration is an essential part of&#x000a0;patient safety in the inpatient and outpatient setting.&#x000a0;</p>
      </sec>
      <sec id="article-125954.s5">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=125954&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=125954">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/125954/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=125954">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-125954.s6">
        <fig id="article-125954.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Pharmacy Calculations: Figure 3: The relationship between pharmacokinetics and pharmacodynamics. Contributed by Piyush Sharma, MDc</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="IMG_6651" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-125954.s7">
        <title>References</title>
        <ref id="article-125954.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caldwell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Swales</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>An introduction to drug disposition: the basic principles of absorption, distribution, metabolism, and excretion.</article-title>
            <source>Toxicol Pathol</source>
            <year>1995</year>
            <season>Mar-Apr</season>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>102</fpage>
            <page-range>102-14</page-range>
            <pub-id pub-id-type="pmid">7569663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125954.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feucht</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Principles of pharmacology.</article-title>
            <source>Pediatr Clin North Am</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-9, ix</page-range>
            <pub-id pub-id-type="pmid">21281845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125954.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Currie</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology, Part 2: Introduction to Pharmacokinetics.</article-title>
            <source>J Nucl Med Technol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>46</volume>
            <issue>3</issue>
            <fpage>221</fpage>
            <page-range>221-230</page-range>
            <pub-id pub-id-type="pmid">29724803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125954.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dong</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Current Strategies for Brain Drug Delivery.</article-title>
            <source>Theranostics</source>
            <year>2018</year>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>1481</fpage>
            <page-range>1481-1493</page-range>
            <pub-id pub-id-type="pmid">29556336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125954.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Batchelor</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Marriott</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Paediatric pharmacokinetics: key considerations.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>79</volume>
            <issue>3</issue>
            <fpage>395</fpage>
            <page-range>395-404</page-range>
            <pub-id pub-id-type="pmid">25855821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125954.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mansoor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mahabadi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <chapter-title>Volume of Distribution</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">31424864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125954.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Starkey</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Sammons</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Practical pharmacokinetics: what do you really need to know?</article-title>
            <source>Arch Dis Child Educ Pract Ed</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>100</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-43</page-range>
            <pub-id pub-id-type="pmid">25122157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125954.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grandbois</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rief</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clausen-Schaumann</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gaub</surname>
                <given-names>HE</given-names>
              </name>
            </person-group>
            <article-title>How strong is a covalent bond?</article-title>
            <source>Science</source>
            <year>1999</year>
            <month>Mar</month>
            <day>12</day>
            <volume>283</volume>
            <issue>5408</issue>
            <fpage>1727</fpage>
            <page-range>1727-30</page-range>
            <pub-id pub-id-type="pmid">10073936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125954.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernhardt</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Cytochromes P450 as versatile biocatalysts.</article-title>
            <source>J Biotechnol</source>
            <year>2006</year>
            <month>Jun</month>
            <day>25</day>
            <volume>124</volume>
            <issue>1</issue>
            <fpage>128</fpage>
            <page-range>128-45</page-range>
            <pub-id pub-id-type="pmid">16516322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125954.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boucher</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic changes in critical illness.</article-title>
            <source>Crit Care Clin</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>255</fpage>
            <page-range>255-71, vi</page-range>
            <pub-id pub-id-type="pmid">16677999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125954.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhivkova</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Mandova</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Doytchinova</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Quantitative Structure - Pharmacokinetics Relationships Analysis of Basic Drugs: Volume of Distribution.</article-title>
            <source>J Pharm Pharm Sci</source>
            <year>2015</year>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>515</fpage>
            <page-range>515-27</page-range>
            <pub-id pub-id-type="pmid">26517139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125954.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonzalez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Conrado</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Theuretzbacher</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Derendorf</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The effect of critical illness on drug distribution.</article-title>
            <source>Curr Pharm Biotechnol</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>2030</fpage>
            <page-range>2030-6</page-range>
            <pub-id pub-id-type="pmid">21554214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125954.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Almazroo</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Miah</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Venkataramanan</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Drug Metabolism in the Liver.</article-title>
            <source>Clin Liver Dis</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-20</page-range>
            <pub-id pub-id-type="pmid">27842765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125954.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manikandan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nagini</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cytochrome P450 Structure, Function and Clinical Significance: A Review.</article-title>
            <source>Curr Drug Targets</source>
            <year>2018</year>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-54</page-range>
            <pub-id pub-id-type="pmid">28124606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125954.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al Raiisi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fernandez-Llimos</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Salgado</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Mohamed</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacy practice in the care of Chronic Kidney Disease patients: a systematic review.</article-title>
            <source>Int J Clin Pharm</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>630</fpage>
            <page-range>630-666</page-range>
            <pub-id pub-id-type="pmid">30963447</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125954.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mardani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vaismoradi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The Role of the Nurse in the Management of Medicines During Transitional Care: A Systematic Review.</article-title>
            <source>J Multidiscip Healthc</source>
            <year>2020</year>
            <volume>13</volume>
            <fpage>1347</fpage>
            <page-range>1347-1361</page-range>
            <pub-id pub-id-type="pmid">33154651</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
